Bavarian Nordic (OTCMKTS:BVNRY) Sees Significant Decrease in Short Interest

Bavarian Nordic (OTCMKTS:BVNRY) was the recipient of a significant decline in short interest during the month of September. As of September 15th, there was short interest totaling 833 shares, a decline of 44.7% from the August 31st total of 1,506 shares. Based on an average daily volume of 1,944 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.0% of the company’s stock are short sold.

Bavarian Nordic Price Performance

Shares of OTCMKTS:BVNRY opened at $10.81 on Friday. Bavarian Nordic has a 1 year low of $8.67 and a 1 year high of $13.00. The company has a market cap of $2.57 billion, a P/E ratio of 10.92 and a beta of 1.25. The stock’s fifty day moving average price is $10.26 and its 200-day moving average price is $9.88.

Bavarian Nordic (OTCMKTS:BVNRY) last released its quarterly earnings data on Friday, August 21st. The company reported $0.46 EPS for the quarter. Bavarian Nordic had a return on equity of 11.97% and a net margin of 24.36%.The company had revenue of $316.47 million during the quarter.

About Bavarian Nordic

Bavarian Nordic A/S is a Denmark-based biotechnology company focused on developing, manufacturing and commercializing vaccines. The company serves government agencies, healthcare providers, travelers and other customers through a portfolio of products addressing infectious diseases and public-health preparedness.

Its best-known vaccine is MVA-BN, marketed as Jynneos in the United States and Imvanex in the European Union, for protection against smallpox and mpox. Bavarian Nordic also markets vaccines for rabies, including Rabipur and RabAvert, and for tick-borne encephalitis under the Encepur brand.